The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Angiotensin Ii Receptor Blockers
Open accessAbstract
The ARBs have very similar clinical profiles. They do, however, have different pharmacokinetic profiles, which may lead to some differences in efficacy. The newer agents irbesartan, candesartan, telmisartan, and olmesartan have longer half-lives and durations of action than the older agents losartan and valsartan (5). Twenty-four–hour blood pressure control could be more readily achievable with the newer agents. Losartan and valsartan may need to be administered twice daily in patients needing greater antihypertensive effects, whereas the agents with longer durations of action have no added benefit when administered more than once daily. Of course, a once-daily product is always preferred. Several double-blind, head-to-head comparative trials have evaluated the relative antihypertensive efficacy of the ARBs in patients with mild to moderate hypertension. The net result is that the longer-acting agents may be more effective than losartan and valsartan at providing 24-hour blood pressure control. But, as also mentioned, a metaanalysis of 43 trials comparing the antihypertensive effects of ARBs found comparable antihypertensive efficacies within the ARB class (4, 5). Whether reported differences in efficacy are clinically relevant regarding morbidity and mortality has not been determined. When evaluating differences among the ARBs, their current and future places in therapy for unlabeled uses must be considered. ARBs have been evaluated for use in heart failure, as combination therapy with ACE inhibitors and alone as standard therapy. Losartan and valsartan are the only ARBs for which studies have been completed that involved long-term follow-up with morbidity and mortality as endpoints. Neither agent can replace ACE inhibitors as first-line therapy, but both remain a rational alternative for patients unable to tolerate ACE inhibitors. Candesartan is currently being evaluated for this same use.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure
Cohn, J. N., & Tognoni, G. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010713 · Cited by 3,108
Cited by
Acute Myocardial Infarction in Women: A Scientific Statement From the American Heart Association
Mehta, L. S., Beckie, T. M., DeVon, H. A., Grines, C. L., Krumholz, H. M., Johnson, M. N., Lindley, K. J., Vaccarino, V., Wang, T. Y., Watson, K. E., et al. (2016) · Circulation · doi:10.1161/cir.0000000000000351 · Cited by 1,244
Drug repurposing approach to fight COVID-19
Singh, T. U., Parida, S., Lingaraju, M. C., Kesavan, M., Kumar, D., & Singh, R. K. (2020) · Pharmacological Reports · doi:10.1007/s43440-020-00155-6 · Cited by 480
A Brief Review of Cardiovascular Diseases, Associated Risk Factors and Current Treatment Regimes
Flora, G. D., & Nayak, M. K. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190925163827 · Cited by 476
The renin-angiotensin system and malignancy
Ager, E. I., Neo, J., & Christophi, C. (2008) · Carcinogenesis · doi:10.1093/carcin/bgn171 · Cited by 295
SARS-CoV-2 Infection and COVID-19 During Pregnancy: A Multidisciplinary Review
Narang, K., Enninga, E. A. L., Gunaratne, M. D. S. K., Ibirogba, E. R., Trad, A. T. A., Elrefaei, A., Theiler, R. N., Ruano, R., Szymanski, L. M., Chakraborty, R., et al. (2020) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2020.05.011 · Cited by 279
Metadata
- Authors
- Barreras, A., & Gurk-Turner, C.
- Venue
- Baylor University Medical Center Proceedings
- Publisher
- Informa UK Limited
- Published
- 2003-01
- Volume
- 16
- Issue
- 1
- Pages
- 123-126
- ISSN
- 0899-8280 (ISSN-L)
- 1525-3252
- OpenAlex
- W1510066062
- Cited by
- 174
- References
- 1
- FWCI
- 2.51
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.